Accordingly, anti-angiogenic drugs targeting VEGF-A, VEGF-B, fibroblast growth factor (FGF), transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) have been successfully incorporated in the clinical practice to battle cancer. Here, VEGFA is linked to cancer.